Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Elafibranor in Hepatic Impairment
NCT03765671Phase 1Completed
- Sponsor
- Genfit
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elafibranor in primary biliary cholangitis (PBC) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Genfit. Primary endpoints: Area under curve from dosing time to last measurement at 384 hours and Area under curve from dosing time to infinity at 384 hours. Started Dec 2018; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03765671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765671.